

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.
InforMEDical Communications, Inc. •
83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com
Table of Contents
Thomas J. Lynch, Jr, MD
Director, Yale Cancer Center, Physician-in-Chief
Smilow Cancer Center at Yale, New Haven
Role of Maintenance Monoclonal Antibodies
Alan B. Sandler, MD
Division Chief, Hematology/Oncology
Oregon Health and Science University, Portland
Evidence for Early Second-Line Therapy: Docetaxel and Erlotinib
Panos Fidias, MD
Clinical Director, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center, Boston
Evidence for Early Second-Line Therapy: Pemetrexed
Nasser H. Hanna, MD, and Shadia Jalal, MD
Division of Hematology/Oncology
Indiana University School of Medicine, Indianapolis
Determining Which Approach Is Best for Your Patient
Discussion of relevant case studies presented by Dr. Lynch